Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT02930954 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: Gefitinib
DRUG: pemetrexed or gemcitabine plus carboplatin,
DRUG: bevacizumab

Sponsor

Caicun Zhou